GlaxoSmithKline Granted Europe Marketing Authorisation For Relvar Ellipta

Mon, 18th Nov 2013 13:31

LONDON (Alliance News) - GlaxoSmithKline PLC Monday said that the European Commission has granted marketing authorisation for asthma and chronic pulmonary disease drug Relvar Ellipta, which is now licenced across 31 European countries.

The pharmaceuticals giant said that under the terms of a 2002 collaboration, Theravance Inc. is obligated to make a milestone payment to Glaxo of USD15 million following the marketing authorisation.

Glaxo shares were up 0.4% to 1,621.5 pence Monday.

By Tom McIvor; tommcivor@alliancenews.com; @TomMcIvor1

Related Shares

More News

Today 08:25

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a ...

24 Jun 2024 08:55

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

24 Jun 2024 07:43

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included...

24 Jun 2024 07:21

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or ...

20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has rece...